Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
Launched by JEFF BRIDGE · May 23, 2022
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called TAILOR, is studying a new program designed to help teenagers who have trouble sleeping and are at risk for suicidal thoughts or behaviors. The program focuses on improving sleep through specific strategies to help young people fall asleep more easily and get better rest. By addressing sleep issues, the researchers hope to reduce the overall risk of suicidal behavior among adolescents.
To participate in this study, young people must be between 11 and 18 years old and have recently experienced both sleep problems and thoughts of suicide. They also need to live with a caregiver who can give permission for them to join the study. Participants will receive support and guidance to improve their sleep, but there are some health conditions that would exclude someone from joining, such as recent suicide attempts or certain sleep disorders. If eligible, participants can expect to learn helpful skills to manage their sleep and improve their overall well-being in a supportive environment.
Gender
ALL
Eligibility criteria
- Inclusion:
- • Nationwide Children's Hospital patients
- • Between the ages of 11 years, 0 months, and 18 years, 11 months, inclusive at time of consent
- • Endorse both recent (past 90 days) suicidal ideation and sleep problems (past 30 days)
- • Resides with primary caregiver who has legal authority to consent to research participation
- Exclusion:
- • Suicide attempt in the past 3 months
- • Diagnosis of Bipolar Disorder or Psychosis
- • Having a change to an antipsychotic and/or mood stabilizer medication regimen within the last 2 months
- • Snoring at least 3 nights per week that can be heard a room or two away, even without a cold or flu or during allergy season
- • Gasping for air while sleeping, diagnosis of Obstructive Sleep Apnea, or turning blue within the past year
- • Body Mass Index \> 40
- • Daytime symptoms of Restless Leg Syndrome
- • Diagnosis of Narcolepsy
- • Diagnosis of Seizures or Epilepsy, or prescribed anticonvulsant medication, within the past 4 years
- • Significant substance use in the past month
- • Currently receiving sleep disorder services from a sleep clinic
- • Inability to speak/read English adequately to understand and complete study consent and procedures
- • No access to a telephone or internet-connecting device
- • Sibling already in the study
About Jeff Bridge
Jeff Bridge is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, the organization collaborates with leading research institutions and healthcare professionals to conduct rigorously designed clinical trials. Jeff Bridge emphasizes ethical standards, transparency, and patient safety throughout the trial process, aiming to contribute significantly to the scientific community and enhance treatment options across various therapeutic areas. Through its commitment to excellence and collaboration, Jeff Bridge strives to drive progress in healthcare and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Patients applied
Trial Officials
Jeff Bridge, Ph.D.
Principal Investigator
Nationwide Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials